Building a GCT Portfolio
Thursday, May 20, 2021
GCT represents a large and growing market for novel therapeutics that has several segments. These include Cardiovascular Disease, Cancer, Neurological Diseases, Infectious Disease, Ophthalmology, Benign Blood Disorders, and many others; Manufacturing and Supply Chain including CDMO’s and CMO’s; Stem Cells and Regenerative Medicine; Tools and Platforms (viral vectors, nano delivery, gene editing, etc.). Bayer’s pharma business participates in virtually all of these segments. How does a Company like Bayer approach the development of a portfolio in a space as large and as diverse as this one? How does Bayer approach the support of the production infrastructure with unique demands and significant differences from its historical requirements?
- Moderator:
-
- Ansbert Gadicke, MD
-
- Co-Founder, Managing Director, MPM Capital
- Speaker:
-
- Wolfram Carius, PhD
-
- EVP, Pharmaceuticals, Head of Cell & Gene Therapy, Bayer AG
-
Q&A
01:00 PM – 01:15 PM